The contribution of MECOM network enrichment to clinical risk grouping was even more striking in the pediatric AML cohort in which MECOM network enrichment was significantly associated with mortality independent of clinical risk group (P = 0.008) (Fig. 7h) and, separately, independent of LSC17 score (P = 0.01) (Fig. 7i). This evidence concerns the gene MECOM and acute myeloid leukemia.